Shutterstock.com
Smoking cessation therapy bupropion will resume supplies to the UK from December 2023, its manufacturer GSK has said, after the product was withdrawn from the market following concerns over potential nitrosamine impurities.
The return of bupropion supplies follows updated guidance from the European Medicines Agency (EMA) on nitrosamine impurities, published in July 2023, which sets out a 1500 nanogram/day limit for acceptable daily intake of n-nitroso-bupropion.
In a statement to The Pharmaceutical Journal on 29 August 2023, a spokesperson for GSK, which markets bupropion as Zyban, said that, as a result of the updated guidance, supplies of “Zyban tablets will be resumed across the EU and Europe on or before the end of December 2023”.
In 2019, the EMA, along with other medicines regulators around the world, asked marketing authorisation holders to carry out a comprehensive review of all chemical and biological human medicines for the possible presence of nitrosamines, which are probable human carcinogens.
Following its review, GSK said it had placed an immediate hold on batch release and distribution of bupropion 150mg tablets in November 2022, having found the potential for the presence of nitrosamine N-nitroso-bupropion at levels above the EMA’s temporary acceptable intake limit.
GSK confirmed that supplies of bupropion would return to the UK as part of its plans to resume distribution across Europe.
On 24 August 2023, the Medicines and Healthcare products Regulatory Agency published a statement announcing that it would look to align its guidance on nitrosamine impurities in medicines “with regulatory authorities like the EMA”.
It added: “We review European Union (EU) decisions on nitrosamine AIs [acceptable intake levels], either recognising EU assessments or conducting national reviews based on product specifics. If AIs are exceeded, we conduct a national assessment for necessary market actions.”
Bupropion is a selective re-uptake inhibitor of noradrenaline and dopamine, which sits under the class of antidepressant drugs. However, in the UK, bupropion is only licensed for smoking cessation.
Since the withdrawal of bupropion — in addition to varenicline, which was withdrawn from use in 2021 also owing to potential nitrosamine impurities — nicotine replacement therapy (NRT) has been the only licensed medicine for smoking cessation in the UK.
Darush Attar-Zadeh, clinical fellow respiratory pharmacist at North West London Integrated Care Board, and co-chair of the Taskforce for Lung Health medicines optimisation working group, said the forthcoming resupply of bupropion was “good news indeed”.
“Bupropion has been available in the UK since 2000 and a good option for many to stop smoking,” he said.
“It’s not as effective as varenicline or combination NRT … [but] I’d like to see it being made more readily available in community pharmacies (under a patient group directive) alongside evidence-based behavioural support,” he added.
Under the NHS smoking cessation service, community pharmacies can supply one of 30 NRTs, including lozenges, gum and patches along with behavioural support. There are no other medicines currently listed under the service.
Since its launch in March 2022, The Pharmaceutical Journal reported that 2,200 pharmacies had signed up to provide the service in the first two months of it going live.
Commenting on the resupply of bupropion, Robert West, professor of health psychology and director of tobacco studies at University College London, said: “Prior to its withdrawal, Zyban was hardly used at all in the UK — [it is] much more popular in the United States, where, of course, the same drug is also widely used for depression, so I would be surprised if it made much of an impact.”
In August 2023, a spokesperson for Pfizer, the manufacturer of varenicline, told The Pharmaceutical Journal that the company was unable to “speculate on resupply timing at this time”.
5 comments
You must be logged in to post a comment.
I was delighted to read that Buproprion will be made available again later this year. A very good friend of mine was prescribed Zyban for Bipolar Disorder and the difference it made to her life was miraculous and it was devastating when it was withdrawn.
I daren't get too excited until GSK confirms it themselves. Return date is still down as 'TBC' on their product supply page. I've emailed them directly but not heard anything yet.
They literally published the update in the Pharmaceutical Journal.
All such statements are thoroughly approved by a legal department beforehand – they're hardly likely to have made this announcement by accident... Trust that you'll have it again in 10 weeks' time! 😊
I have been taking bupropion (off licence) since 2016 for depression after my psychiatrist read that it has been used successfully with autistic patients. He decided to try this 12 months before I got my actual ASD diagnosis. The waiting list for the assessment was 6 years long- I am one of the many middle aged women who have finally been correctly diagnosed after a lifetime of misdiagnoses due to the belief that only boys were effected.
Over the preceding 20 plus years, I had tried the majority of antidepressants with varying levels of short lived success.
I was over the moon to find something that kept me stable.
The past 12 months have been so stressful. Fortunately I have worked as a dispenser in the past and some of my ex colleagues had every locum they worked with scouring the shelves and drawers of all pharmacies they visited. I am grateful to each and every one as they have just about kept my rx filled whilst it has been unavailable. (Shout out to all locums everywhere! Thank you all for being there!)
I had just about given up hope and had arranged meds review with psychiatrist. That appointment is today and I came here to remind myself why it had been stopped so that I could explain the issue. I cannot tell you how pleased I am to see the news that it is coming back!!
I was prescribed this off-label for ADHD, I was able to function 'normally' for the first time in my adult life within a couple of days of starting bupropion. When it was discontinued I went through sheer hell - the past year has been a nightmare: my job has been at risk, I have been suicidal, and was essentially left with no hope. This news is huge and Prof. Robert West needs to revise his comment - to say it will have little impact is ignorant and deeply insulting.